Skip to main content

Specialty Pharmacy

  • Generics to drive down HIV drug sales in next decade

    BURLINGTON, Mass. — The availability of new generic drugs for treating HIV will erode sales of HIV antiretroviral drugs into the next decade in developed countries, according to a new report.

    Healthcare market research firm Decision Resources released the report Wednesday, showing that sales of antiretroviral drugs in the United States, France, Germany, the United Kingdom, Spain, Italy and Japan would be $13.1 billion in 2022, down from 2012's $13.4 billion.

  • Former Genentech COO appointed to Rite Aid board of directors

    CAMP HILL, Pa. — Rite Aid has appointed healthcare executive Myrtle Potter to its board of directors, the retail pharmacy chain said Tuesday.

    Potter is currently CEO of Myrtle Potter & Co., a Silicon Valley-based consulting firm focused on life sciences and health care, as well as the head of consumer healthcare content company Myrtle Potter Media. She previous served as president of commercial operations and COO at Genentech and has worked at companies like Bristol-Myers Squibb and Merck.

  • Impax Labs to market generic or authorized generic version of OxyContin under deal with Purdue Pharma

    HAYWARD, Calif. — Impax Labs has settled a patent-infringement suit filed by Purdue Pharma concerning the opioid painkiller OxyContin, Impax said Tuesday.

  • Reports: R.I. may set up prescription drug registry to combat abuse

    NEW YORK — Officials in Rhode Island may set up a registry that would allow doctors and pharmacists to track patients who have problems with drug abuse, according to published reports.

    The Associated Press reported that the proposed registry would track prescriptions for drugs that are controlled substance and allow healthcare professionals to track their usage, similar to a monitoring program set up in New York this year. A task force that includes state lawmakers, health officials and healthcare professionals met Monday to look at the idea.

  • CMS: Medicare Part D beneficiaries who hit 'doughnut hole' saved $8.9 billion in 2013 thanks to Affordable Care Act

    WASHINGTON — Elderly and disabled people nationwide have saved almost $9 billion on prescription drugs thanks to the Patient Protection and Affordable Care Act, according to a new study by the Centers for Medicare and Medicaid Services.

  • Egalet, Shionogi to develop abuse-deterrent opioids

    MALVERN, Pa. — Shionogi and Egalet have entered a deal worth up to $425 million for the development of abuse-deterrent opioid painkillers, Egalet said.

    The deal centers on the development and potential commercialization of experimental drugs containing the opioid painkiller hydrocodone.

  • Mylan, Elton John AIDS Foundation donate $1 million to end mother-to-child HIV transmission in Nigeria

    PITTSBURGH — Drug maker Mylan and the Elton John AIDS Foundation will donate $1 million to the Business Leadership Council for a Generation Born HIV Free, the two said.

  • FDA gives second orphan drug designation to Teva's Treanda

    JERUSALEM — The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.

    Teva said the drug, Treanda (bendamustine hydrochloride), received the designation for indolent B-cell non-Hodgkins lymphoma through October 2015 that has progressed during or within six months of treatment with a regimen containing Rituxan (rituximab), marketed by Genentech and Biogen Idec. The FDA gives orphan drug designation to treatments for diseases affecting fewer than 200,000 people in the United States.

X
This ad will auto-close in 10 seconds